A Phase I Study of INCB053914 (Pan-PIM Kinase Inhibitor) and Pomalidomide With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Latest Information Update: 21 Aug 2020
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary) ; Uzansertib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
Most Recent Events
- 17 Aug 2020 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 17 Aug 2020 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.
- 17 Aug 2020 Planned initiation date changed from 1 Jul 2020 to 1 Jul 2021.